Label: Information for the User
Travoprost Rafarm 40 micrograms/mL eye drops solution
Read this label carefully before you start using this medicine, because it contains important information for you.
Travoprost Rafarmcontains travoprostwhich is part of a group of medications called prostaglandin analogs. It works by reducing pressure in the eye. It can be used alone or with other eye drops, for example with beta-blockers, which also reduce pressure in the eye.
Travoprost Rafarmis used to reduce high pressure in the eye in adults.This pressure may lead to a disease calledglaucoma.
No use Travoprost Rafarm
Warnings and Precautions
This medication may:
In case of contact with the product on the skin, it should be removed by washing immediately.
Children and Adolescents
Travoprost Rafarm should not be used in individuals under 18 years of age.
Use of Travoprost Rafarm with Other Medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use other medications, including those obtained without a prescription.
Pregnancy and Breastfeeding
Do not use Travoprost Rafarm if you are pregnant.If you think you may be pregnant, tell your doctor immediately. If you can become pregnant, you should use an appropriate contraceptive method while using this medication.
Do not use Travoprost Rafarm if you are breastfeeding.This medication may pass into breast milk.
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor before using this medication.
Driving and Operating Machines
You may notice blurred vision immediately after applying this medication. Do not drive or use machines until this effect has disappeared.
Travoprost Rafarm contains benzalkonium chloride
This medication may produce eye irritation due to the presence of benzalkonium chloride.
Avoid contact with soft contact lenses. Remove contact lenses before application and wait at least 15 minutes before reinserting them. May alter the color of soft contact lenses.
Travoprost Rafarm contains macrogol-15-hydroxystearate
This medication may cause skin reactions due to the presence of macrogol-15-hydroxystearate.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Recommended dose:
Adults:1 drop in the affected eye(s), once a day at night.Only Travoprost Rafarm should be applied in both eyes if your doctor instructs you to do so. Follow the treatment for the entire period of time indicated by your doctor.
Travoprost Rafarm should only be used as eye drops.
If a drop falls outside the eye,try again.
If you use more Travoprost Rafarm than you should
If you have applied more Travoprost Rafarm than you should have, you can remove it by washing your eyes with warm water. Do not apply more drops until your next scheduled dose.
In case of accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to use Travoprost Rafarm
If you forget to apply Travoprost Rafarm, continue with the next scheduled dose.Do notapply a double dose to compensate for the missed dose. Never apply more than 1 drop per day in the affected eye(s).
If you interrupt treatment with Travoprost Rafarm
Do not stop using this medication without consulting your doctor. Your eye pressure will not be controlled, which could cause vision loss.
If you are using another eye drop
Wait at least 5 minutes between applying Travoprost Rafarm and the other drops.
If you have any other questions about using this product, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
If you experience side effects, you can usually continue using the drops unless the side effects are severe. If these side effects concern you, consult your doctor or pharmacist. Do not stop using this medication without consulting your doctor.
The following side effects have been observed with travoprost:
Very common(may affect more than 1 in 10 people)
Common(may affect between 1 and 10 in 100 people)
Eye effects:
Body effects:
Rare(may affect between 1 and 10 in 1,000 people)
Eye effects:
Body effects:
Additional reported side effects include:
Eye effects:
Body effects:
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for human use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
To prevent infections,you must discard the bottle 4 weeks after opening it for the first time,and use a new bottle. Note the opening date in the reserved spaces on the label of each bottle and the box.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy.In case of doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Travoprost Rafarm
Appearance of the product and contents of the packaging
Travoprost Rafarm is a liquid (a colourless and transparent solution) presented in a box containing a plastic vial with a dropper dispenser and a screw cap.
Each vial contains 2.5 ml of solution.
Containers containing 1 vial.
Holder of the marketing authorization
Rafarm S.A.
12 Korinthou str., N. Psihiko
15451, Attiki
Greece
Responsible for manufacturing
Rafarm S.A.
Thesi Pousi-Hatzi Agiou Louka, Paiania-Attiki, TK 19002, P.O. 37, Greece
Local Representative
Cipla Europe NV subsidiary in Spain
C/Guzmán el Bueno, 133 Edif Britannia-28003- Madrid
Spain
Last review date of this leaflet: November 2014.
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.